584 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Bought by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 584 shares of the company’s stock, valued at approximately $47,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AXSM. TD Asset Management Inc acquired a new position in Axsome Therapeutics during the fourth quarter worth $1,273,000. CIBC Private Wealth Group LLC increased its position in Axsome Therapeutics by 0.8% during the fourth quarter. CIBC Private Wealth Group LLC now owns 17,999 shares of the company’s stock worth $1,433,000 after buying an additional 135 shares in the last quarter. Lighthouse Investment Partners LLC purchased a new position in Axsome Therapeutics during the fourth quarter worth $4,473,000. Bellevue Group AG increased its position in Axsome Therapeutics by 0.6% during the fourth quarter. Bellevue Group AG now owns 635,372 shares of the company’s stock worth $50,569,000 after buying an additional 3,885 shares in the last quarter. Finally, Superstring Capital Management LP purchased a new position in Axsome Therapeutics during the fourth quarter worth $1,288,000. 81.49% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have weighed in on AXSM. Cantor Fitzgerald reissued an “overweight” rating and set a $107.00 price target on shares of Axsome Therapeutics in a research report on Monday, September 16th. Needham & Company LLC reissued a “buy” rating and set a $130.00 price target on shares of Axsome Therapeutics in a research report on Thursday, September 5th. Mizuho reissued a “buy” rating and set a $106.00 price target on shares of Axsome Therapeutics in a research report on Wednesday, June 12th. StockNews.com raised Axsome Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 1st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $180.00 price objective on shares of Axsome Therapeutics in a research report on Thursday, September 5th. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $124.64.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, COO Mark L. Jacobson sold 47,739 shares of the business’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $84.26, for a total transaction of $4,022,488.14. Following the completion of the sale, the chief operating officer now owns 5,783 shares of the company’s stock, valued at approximately $487,275.58. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Axsome Therapeutics news, COO Mark L. Jacobson sold 47,739 shares of the business’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $84.26, for a total transaction of $4,022,488.14. Following the transaction, the chief operating officer now owns 5,783 shares in the company, valued at $487,275.58. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Mark E. Saad sold 11,016 shares of the business’s stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $91.31, for a total value of $1,005,870.96. Following the transaction, the director now owns 10,002 shares in the company, valued at approximately $913,282.62. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 22.40% of the stock is owned by company insiders.

Axsome Therapeutics Price Performance

AXSM stock opened at $86.59 on Friday. The stock has a 50-day moving average price of $89.04 and a two-hundred day moving average price of $80.88. Axsome Therapeutics, Inc. has a 12-month low of $55.02 and a 12-month high of $98.40. The company has a current ratio of 2.48, a quick ratio of 2.40 and a debt-to-equity ratio of 1.77. The company has a market cap of $4.11 billion, a PE ratio of -13.57 and a beta of 1.26.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Monday, August 5th. The company reported ($1.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.30) by $0.06. Axsome Therapeutics had a negative return on equity of 117.46% and a negative net margin of 105.85%. The firm had revenue of $87.17 million during the quarter, compared to the consensus estimate of $84.53 million. As a group, research analysts predict that Axsome Therapeutics, Inc. will post -4.73 EPS for the current year.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.